echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Fuhong Henlius' innovative anti-PD-L1/TIGIT dual antibody was approved to carry out clinical trials in Australia

    Fuhong Henlius' innovative anti-PD-L1/TIGIT dual antibody was approved to carry out clinical trials in Australia

    • Last Update: 2022-01-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>


    In recent years, immune checkpoint therapy has provided a new way for tumor treatment


    HLX301 is an innovative anti-PD-L1 and anti-TIGIT bispecific antibody independently developed by Henlius.


    Starting from clinical needs, Henlius has now created a diversified pipeline of innovative products, with a comprehensive layout at PD-1/L1, CTLA-4, LAG-3 and other immune checkpoints, creating more for the exploration of combined immunotherapy Possible


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.